Joseph P. Hagan - Jan 3, 2022 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Role
Director
Signature
/s/ Joseph P. Hagan
Stock symbol
AUPH
Transactions as of
Jan 3, 2022
Transactions value $
-$700,450
Form type
4
Date filed
1/4/2022, 03:17 PM
Previous filing
Jun 16, 2021
Next filing
Jan 26, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AUPH Common Stock Options Exercise $203K +40K +1142.86% $5.08 43.5K Jan 3, 2022 Direct F1
transaction AUPH Common Stock Sale -$889K -39.4K -90.5% $22.58 4.13K Jan 3, 2022 Direct F2, F3
transaction AUPH Common Stock Sale -$14.8K -634 -15.34% $23.29 3.5K Jan 3, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AUPH Stock Option (right to buy) Options Exercise $0 -40K -80% $0.00 10K Jan 3, 2022 Common Stock 40K $5.08 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.27 to $23.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date.